Oppenheimer analyst Mark Breindenbach lowered the price target on BioLineRx (NASDAQ: BLRX) to $10.00 (from $11.00) while maintaining an Outperform ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE